Edition:
United Kingdom

Solid Biosciences Inc (SLDB.OQ)

SLDB.OQ on NASDAQ Stock Exchange Global Select Market

5.52USD
24 May 2019
Change (% chg)

$-0.21 (-3.66%)
Prev Close
$5.73
Open
$5.72
Day's High
$5.83
Day's Low
$5.41
Volume
88,312
Avg. Vol
250,841
52-wk High
$54.51
52-wk Low
$5.24

Latest Key Developments (Source: Significant Developments)

Solid Biosciences Files For Mixed Shelf Of Upto $200 Mln
Wednesday, 13 Mar 2019 

March 13 (Reuters) - Solid Biosciences Inc ::SOLID BIOSCIENCES FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING.  Full Article

Solid Biosciences Announces Preliminary SGT-001 Data And Intention To Dose Escalate In Ignite DMD Clinical Trial For Duchenne Muscular Dystrophy
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Solid Biosciences Inc ::SOLID BIOSCIENCES ANNOUNCES PRELIMINARY SGT-001 DATA AND INTENTION TO DOSE ESCALATE IN IGNITE DMD CLINICAL TRIAL FOR DUCHENNE MUSCULAR DYSTROPHY.SOLID BIOSCIENCES INC - COMPANY EXPEDITING PLANNED DOSE ESCALATION ACTIVITIES.SOLID BIOSCIENCES INC - SAFETY PROFILE OF SGT-001 REMAINS UNCHANGED AND ALL PATIENTS CONTINUE TO BE FOLLOWED PER STUDY PROTOCOL.SOLID BIOSCIENCES - EXISTING CASH, CASH EQUIVALENTS & AVAILABLE-FOR-SALE SECURITIES AS OF SEPT 30, TO BE SUFFICIENT TO FUND OPERATIONS THROUGH Q1 2020.  Full Article

Solid Biosciences Announces Clinical Hold On SGT-001 Phase I/Ii Clinical Trial
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Solid Biosciences Inc ::SOLID BIOSCIENCES ANNOUNCES CLINICAL HOLD ON SGT-001 PHASE I/II CLINICAL TRIAL FOR DUCHENNE MUSCULAR DYSTROPHY.SOLID BIOSCIENCES - FIRST PATIENT DOSED IN CLINICAL TRIAL WAS NON-AMBULATORY ADOLESCENT WHO RECEIVED 5E13 VG/KG OF SGT-001 ON FEB. 14.SOLID BIOSCIENCES - SEVERAL DAYS AFTER ADMINISTRATION PATIENT WAS HOSPITALIZED DUE TO LABORATORY FINDINGS THAT INCLUDED DECREASE IN PLATELET COUNT.SOLID BIOSCIENCES INC - ‍SOLID REPORTED EVENT TO FDA AND, BECAUSE IT WAS UNEXPECTED, CLASSIFIED IT AS A SUSAR​.SOLID BIOSCIENCES INC - ‍HAS HALTED ENROLLMENT AND DOSING IN IGNITE DMD AND IS AWAITING FORMAL CLINICAL HOLD LETTER FROM FDA​.SOLID BIOSCIENCES - PATIENT DOSED IN SGT-001 TRIAL ALSO SHOWED REDUCTION IN RED BLOOD CELL COUNT AND EVIDENCE OF COMPLEMENT ACTIVATION.SOLID BIOSCIENCES - PATIENT DOSED IN SGT-001 TRIAL SHOWED NO SIGNS OF COAGULOPATHY AND NO RELEVANT CHANGES FROM BASELINE IN LIVER FUNCTION TESTS.SOLID BIOSCIENCES INC - ‍AFFECTED PATIENT RESPONDED WELL TO MEDICAL TREATMENT AND IS CURRENTLY ASYMPTOMATIC​.  Full Article

Perceptive Advisors Reports 11.5 Pct Stake In Solid Biosciences As Of Jan 30
Thursday, 8 Feb 2018 

Feb 8 (Reuters) - Solid Biosciences Inc ::PERCEPTIVE ADVISORS LLC REPORTS 11.5 PERCENT STAKE IN SOLID BIOSCIENCES INC AS OF JAN 30 - SEC FILING.  Full Article

BCLS SB Investco LP Reports 5.8 Pct Stake In Solid Biosciences As Of Jan 25
Thursday, 1 Feb 2018 

Feb 1 (Reuters) - Solid Biosciences Inc ::BCLS SB INVESTCO LP REPORTS 5.8 PERCENT STAKE IN SOLID BIOSCIENCES INC AS OF JAN 25 - SEC FILING.  Full Article

Solid Biosciences Says Now Sees IPO Of 7 Mln Shares Of Common Stock Priced Between $18-$19/Shr - SEC Filing
Wednesday, 24 Jan 2018 

Jan 24 (Reuters) - Solid Biosciences Llc ::SOLID BIOSCIENCES LLC SAYS NOW SEES IPO OF 7.0 MILLION SHARES OF COMMON STOCK PRICED BETWEEN $18.00 AND $19.00 PER SHARE - SEC FILING.SOLID BIOSCIENCES LLC SAYS IT HAD PREVIOUSLY EXPECTED IPO OF UP TO 5.9 MILLION SHARES OF COMMON STOCK PRICED BETWEEN BETWEEN $16.00 AND $18.00 PER SHARE.SOLID BIOSCIENCES LLC SAYS INTENDS TO USE ABOUT $150 MILLION OF IPO PROCEEDS TOGETHER WITH EXISTING CASH, CASH EQUIVALENTS TO FUND RESEARCH AND DEVELOPMENT EXPENSES.  Full Article

UPDATE 1-Gene therapy stocks plunge after poor trial data

Feb 7 Shares of U.S. gene therapy companies sank on Thursday after drugs developed by two small firms failed to show promise in separate clinical trials, underscoring the challenges in an emerging, lucrative field of biotech.